Home Archive
Archive
2022 Volume 53 Issue 7  Published: 2022-07-10
    Perspectives
  • Jun DONG , Xuyu CHAI , Jian WANG
    doi: 10.16522/j.cnki.cjph.2022.07.001

    Gastroretentive drug delivery system(GRDDS) can reduce the frequency of administration and improve the efficacy by prolonging the residence time of drugs in the stomach through physical and chemical effects. However, the real retention effect in human body is often affected by individual differences, physiology, diet and other factors, so it is difficult to achieve the stable gastric retention of more than 24 h in the real sense. Ultra-long-acting GRDDS is one of the unique innovative breakthroughs in the field of oral formulations in recent years. Through the subversive design of mechanical changes(stellate structure and spring coil), ultra-long-acting GRDDS greatly enhances the ability to resist the destruction of stomach physiological factors, making it possible to realize stable gastric retention for more than 24 h or even up to 1 month. If it can be further improved in safety and quality, ultra-long-acting GRDDS will make a great breakthrough in the field of oral preparations. In this paper, the development of ultra-long-acting GRDDS in recent years is reviewed, and its technical challenges and application prospects are analyzed and prospected.

  • Review
  • Jie GAO , Qi ZHANG , Wenzhe WU
    doi: 10.16522/j.cnki.cjph.2022.07.002

    In recent years, pulmonary inhalation of drug-loaded liposomes has attracted extensive attention due to its unique release characteristics and clinical values. This review introduces the advantages of inhaled liposomes, such as reducing the irritation of drugs to lung tissue and extending the retention time of drugs in the lung. Furthermore, the commonly used liposome preparation technologies(e.g., crossflow technology) and the inhalation methods are emphatically described. Then, the marketing and clinical situations of liposome inhalation preparations are briefly introduced. It is hoped to provide literature support for the study of the liposome pulmonary inhalation route for administration.

  • Review
  • Weicheng ZHOU , Pengfei YUE , Fangfang LEI , Yingchong CHEN , Ming YANG
    doi: 10.16522/j.cnki.cjph.2022.07.003

    Drug-in-CD-in-liposome(DCL) is a new drug delivery system that encapsulates cyclodextrin inclusion complexes into liposomes, so it combines the advantages of the two drug delivery systems. DCL can effectively avoid the leakage and rapid release of lipophilic drugs incorporated in the membrane bilayers, which is beneficial to maintain the integrity of liposomes. The dual protection of cyclodextrin and liposome can drastically improve the stability of light-sensitive and heat-sensitive drugs. It allows better control of the release behaviors of drugs and improves the therapeutic effect of drugs. DCL has a wide range of applicable drugs and shows promising properties for applications. This paper reviews the classification, preparation methods, characteristics, and application progress of DCL in drug delivery, which provides methods and references for developing DCLs as a drug delivery system.

  • Review
  • Xiaoping FANG , Yi HU , Shan LU , Yan CAO
    doi: 10.16522/j.cnki.cjph.2022.07.004

    In recent years, the co-amorphous drug formulations have gradually become a new type of drug delivery system with great potential. Co-amorphous drug formulations can improve the stability of amorphous drugs and improve the solubility and dissolution of poorly water-soluble drugs, thereby potentially improving their bioavailability and therapeutic effects. This paper reviews co-amorphous drugs from the perspectives of preparation methods, physicochemical properties, physical stability, and in vitro performance, and clarifieds the in vivo advantages of co-amorphous drugs through a review of the pharmacokinetics of several classic drugs. In particular, the advantages of co-amorphous drugs in theory, preparation technology, and physicochemical properties are discussed to provide a reference for the further development of high-quality co-amorphous drug formulations.

  • Paper
  • Min LI , Bibo HONG , Yinbo CHEN , Liang HU , Xiangkui LIU
    doi: 10.16522/j.cnki.cjph.2022.07.005

    In this report, 4-nitrophenylacetic acid(5) reacted with acetic anhydride to give 1-(4-nitrophenyl)-propan-2-one(6). Condensation of 6 with ethyl cyanoacetate followed by cyclization with sulfur afforded ethyl 2-amino-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate(7), which was acylated with butyl chloroformate to afford ethyl 2-[(butoxycarbonyl)amino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate(8). Then 8 was substituted with 2,6-difluorobenzyl chloride and the resulting product ethyl 2-[(butoxycarbonyl)(2,6-difluorobenzyl)amino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate(9) was reacted with N-bromosuccinimide and dimethylamine to generate ethyl 2-[(butoxycarbonyl)(2,6-difluorobenzyl)amino]-4-[(dimethylamino)methyl]-5-(4-nitrophenyl)thiophene-3-carboxylate(11). And then 2-[(butoxycarbonyl)(2,6-difluorobenzyl)amino]-4-[(dimethylamino)methyl]-5-(4-nitrophenyl)thiophene-3-carboxylic acid(12) was obtained after hydrolysis of 11 with potassium hydroxide. Next, 12 was subjected to condensation with 3-amino-6-methoxypyridazine and cyclization with sodium methoxide to result in 1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-6-(4-nitrophenyl)thieno[2,3-d]-pyrimidine-2,4(1H,3H)-dione(14). Then 14 reacted with hydrogen under catalysis of Pd/C to afford 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione(15). Finally, Substitution of 15 with phenyl chloroformate and methoxamine hydrochloride reduction to prepare relugolix(1) with an overall yield of 22.9% (based on 5).

  • Paper
  • Yongfu QIU , Lu TANG , Lei HUANG , Xuyan LIU , Feng NI , Guan WANG
    doi: 10.16522/j.cnki.cjph.2022.07.006

    This study improved the synthesis process of perampanel(1). 5-Bromo-2-methoxypyridine(3) was prepared by bromination of 2-methoxypyridine(2), and then Kumada coupling of 3 with 2-bromopyridine was carried out to prepare 6'-methoxy-2,3'-bipyridine(4), followed by the hydrolysis with hydrochloric acid to obtain [2,3'-bipyridyl]-6'(1'H)-one(6), the latter underwent the Chan-Evans-Lam coupling reaction with phenylboronic anhydride to give 1'-phenyl-[2,3'-bipyridyl]-6'(1'H)-one(7), which was then brominated with NBS to give 5'-bromo-1'-phenyl-[2',3-dipyridyl]-6(1'H)one(8), finally the Suzuki coupling of 8 with 2-(1,3,2-dioxaborexan-2-yl) benzonitrile(9) in palladium acetate/occurred under the catalysis of triphenylphosphine to give 1 with a total yield of 34% (based on 2).

  • Paper
  • Liguang ZHANG , Jie YU , Lina HAO , Haoteng GU , Zhiwen CHENG
    doi: 10.16522/j.cnki.cjph.2022.07.007

    5-Bromo-2-chloro-4-(cyclopentamino) pyrimidine(3) was prepared by substitution of 5-bromo-2,4-dichloropyrimidine(2). Subsequently, 3 was used to synthesize 3-[2-chloro-4-(cyclopentylamino)pyrimidin-5-yl]prop-2-yn-1-ol(4) through Sonogashira coupling reaction. Next, 4 was subjected to cyclization in the presence of tetrabutylammonium fluoride to produce (2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol(5). The oxidation of 5 by 2,2,6,6-tetramethylpiperidine 1-oxyl(TEMPO)/NaClO2 in flow reactor yielded 2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid(6). At last, the key intermediate of ribociclib, 2-chloro-7-cyclopentyl-N, N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide(1) was synthesized by acylation from compound 6 in 51% of overall yield(based on 2) and with 99.2% of HPLC purity. In this paper, DL-α-tocopherol methoxypolyethylene glycol succinate (TPGS-750-M) aqueous solution was used as the reaction solvent to improve the yield of Sonogashira coupling reaction greatly by micellar chemistry. In addition, continuous flow chemistry was adopted to avoid the risks of oxidation reaction and simplify the operations.

  • Paper
  • Xi LI , Yanlin BIAN , Jianwei ZHU , Baohong ZHANG
    doi: 10.16522/j.cnki.cjph.2022.07.008

    This study obtained variable domain of light amyloid AL-09 and Vλ6wil from inclusion bodies through constructing Escherichia coli expression vectors and optimizing the induction conditions. Then the aggregation activity of AL-09 and Vλ6wil in vitro was detected by thioflavin T(ThT) assay, and the cytotoxicity to AC16 cells was preliminarily identified by MTT assay. The results showed that the optimal isopropyl-beta-D-thiogalactopyranoside concentrations for AL-09 and Vλ6wil expression were respectively 0.2 and 0.4 mmol/L, and the optimal expression time was 3 h. Under the optimal condition, the yields could reach around 10 mg/L. Both AL-09 and Vλ6wil were proved to have the capacity to form fibrils in vitro and showed significant cytotoxicity to AC16 cells. In conclusion, we established an inclusion body expression system for light chain amyloid, which provided a specific research basis for the further study of amyloidosis.

  • Paper
  • Xiao WEI , Dandan WANG , Jianguang LU , Yong WU , Haoju HUA , Jun FENG
    doi: 10.16522/j.cnki.cjph.2022.07.009

    In the preparation of recombinant polypeptide and protein drugs, the bovine enterokinase light chain is one of the most widely used tool enzymes. However, its low expression level leads to high production costs. This study used high-density fermentation technology to obtain the extracellular secretion and expression of the bovine enterokinase light chain based on a high-expressing recombinant bacteria screen. The high-density fermentation process of the engineered bacteria was optimized, and the expression yield of the target protein was increased to (478.47±1.70)mg/L. The target protein was separated and extracted from the fermentation liquid by centrifugation, microfiltration, ultrafiltration and ion-exchange chromatography, and the its purity reached (97.94±0.42)%. Finally, the enzymatic properties of the recombinant bovine enterokinase light chain were characterized. This study has opened up the small-scale preparation process route of recombinant bovine enterokinase light chain, paving the way for its application as a tool enzyme in peptide drug production.

  • Paper
  • Hongwei ZHU , Ying LI , Jingjing CHEN , Jiwen ZHANG , Xiaofei WANG
    doi: 10.16522/j.cnki.cjph.2022.07.010

    Dispersion process may affect the stability of budesonide(BUD) suspension for inhalation. In this study, the effects of dispersion parameters on stability of BUD suspension were evaluated by multiple light scattering method among formulations with different dispersion time(lengths 30, 60, 90, 120 min). For dispersion 60 min group, that values of stability index from top & middle suspension system, average level of total system were smaller comparing with other groups. This suggested that the 60 min dispersion group with better stability attribute. To further evaluate stability in storage, samples from different dispersion time lengths group were placed in different conditions, such as high temperature[(60±2)℃] for 0, 5 and 10 days and accelerated condition[(40±2)℃ and relative humidity of (75±5)%] for 0, 10, 15 and 30 days. In the end of storage period, the particle size distribution(PSD) of the BUD particle in suspension was detected by laser particle sizer, and the aerodynamic particle size distribution of the suspension was detected by a new generation impactor. The results showed that there were no significant differences in the PSD and aerodynamic particle size distribution of the suspension obtained at different dispersion time lengths. For accelerated condition groups, the BUD PSD in all different dispersion groups increased with the increase of storage period. Among this, for 60 min dispersion group, the testing value of volume median diameter(VMD) increased, comparing with those of groups with significant differences(P<0.05). These results showed characterization of high thermodynamic stability in 60 min dispersion suspension formulation.

  • Paper
  • Min LI , Qin TAN , Xiaoying HAN , Gelin WU , Yongxiang WANG
    doi: 10.16522/j.cnki.cjph.2022.07.011

    This paper aimed to study the effects of excipients and preparation process on the compressibility of Weisu effervescent tablets. The representative excipients(effervescent disintegrating agent, magnesium stearate and lactose) commonly used in effervescent tablets and Weisu extract were employed in this research, and the tensile strength, parameters in the compression molding process and yield pressure were taken as the evaluation indexes. The effects of preparation process, direct compression and dry granulation tableting techniques, on the compressibility of Weisu effervescent tablets were investigated combined with physical characteristics. The results showed that the physical properties and compaction behavior of the powders were significantly affected by the effervescent disintegrating agent and the preparation process. The Heckel equations showed that the Weisu extract powder mainly exhibited plastic deformation during the compression process. Compared with direct compression, the physical properties of the granules prepared by dry granulation showed significant differences, such as lower compatibility and significantly improved flowability. Compared with direct compaction, dry granulation tableting was more suitable for the preparation of Weisu effervescent tablets when the actual production factors are taken into account.

  • Paper
  • Yuli LI , Zhijie JIANG , Zhendong NIU , Jun WANG , Guanghua ZHANG
    doi: 10.16522/j.cnki.cjph.2022.07.012

    The container closure integrity for prefilled syringes under vaporized hydrogen peroxide(VHP) sterilization in isolators was investigated and its potential risks were discussed. The bacterial solution of Staphylococcus aureus was added into the prefilled syringe, then the syringe was placed in the isolator according to the method of sterility inspection. The surface sterilization was carried out by the VHP sterilization method which had been verified. The ultraviolet(UV) sterilization was used as the control experiment, and the bacterial counts were performed on the contents of prefilled syringes with two sterilization methods. The results showed that under the VHP sterilization, the sealing integrity of the prefilled syringe containers was damaged, and the mortality rate of Staphylococcus aureus in the contents was 90%. It was showed that when the prefilled syringes were subjected to the sterility inspection of VHP sterilization method, VHP would enter the interior through the packaging system, killing the microorganisms might exist in the tested sample.

  • Paper
  • Lin YAO , Furong XIAN , Fangfang ZHANG
    doi: 10.16522/j.cnki.cjph.2022.07.013

    This study established a mass extraction method to test the package integrity of the injection vials. On the basis of rationally setting parameters and preparing negative and positive samples, the test time for vacuuming and detection of micro-leakage was optimized, and the method validation was carried out. In this paper, the results of the mass extraction method to test the package integrity of the injection vials showed that the sample pore size had a good linear relationship with the flow rate, and the detection and the quantification limits were 0.2 and 0.5 μm, respectively. The mass extraction method for the package integrity testing of the injection vials had high sensitivity, good accuracy, daytime stability, and durability. The method established in this study can effectively test the integrity of the vial packaging system and provide an experimental reference for establishing the test standard for the integrity of the vial packaging system.

  • Paper
  • Qian LIU , Dongmei SONG , Wenming JIANG , Jian LE
    doi: 10.16522/j.cnki.cjph.2022.07.014

    An HPLC method was established for the determination of the related substances specified in US pharmacopoeia 40 as impurities A to F in rabeprazole sodium(1) enteric-coated tablets. The Thermo Hypersil BDS C18 column(4.6 mm×250 mm, 5 μm) was used, and the analysis was carried out in the gradient elution mode with acetonitrile∶4.35 g/L dipotassium hydrogen phosphate solution(adjusted to pH 7.0 with phosphoric acid)(5∶95) as mobile phase A, methanol as mobile phase B, and acetonitrile as mobile phase C. The detection wavelength was 280 nm, the column temperature was 45 ℃, and the injection volume was 5 µl. The results showed that it was linear for 1 in the range of 0.3 - 102.5 μg/ml, and the detection limit was 0.3 ng. The peaks of 1 and each impurity could be completely separated, and the excipients did not interfere with the determination. Compared with the method in Chinese pharmacopoeia 2020, the established method not only could accurately determine the common impurity(impurity A)found in twenty-one batches of 1 enteric-coated tablets, but also control other three known impurities(impurity B, C, F), which provided a reference for the improvement of the specification on active pharmaceutical ingredient and the formulation of 1.

  • Paper
  • Meng WANG , Wei TIAN , Yaqin ZHEN , Lingfang WU , Junshan LI , Liying NIU
    doi: 10.16522/j.cnki.cjph.2022.07.015

    An ultra-high performance liquid chromatography-mass spectrometry(UHPLC-MS/MS) method was established for the simultaneous determination of fourteen active ingredients, including neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, caffeic acid, isochlorogenic acid A, rutin, cynaroside, isoquercitrin, rosmarinic acid, diosmin, ferulic acid, scutellarin, luteolin-7-O-β-D-glucuronide and linarin, in Herba Micromeriae biflorae(1). The Acquity UPLC BEH C18 column(2.1 mm×100 mm, 1.7 μm) was used, and the analysis was carried out in the linear gradient elution mode with acetonitrile as mobile phase A and 0.1% formic acid solution as mobile phase B. The flow rate was 0.4 ml/min, the column temperature was 35 ℃ and the injection volume was 2 μl. The electron spray ionization(ESI) and multiple reaction monitoring(MRM) mode were used, and combined with cluster analysis, principal component analysis and orthogonal partial least squares-discriminant analysis to evaluate the differences of different batches of 1. The results showed that the linear relationship, precision, stability, repeatability and sample recovery of the fourteen compounds were all met the requirements. The chemometric analysis results showed that there were certain differences of the fourteen compounds in 1 from two origins in Yunnan and Sichuan, among which rosmarinic acid and linarin were the main differential components. The established UHPLC-MS/MS method is accurate, rapid, simple and highly sensitive, which provides a reference for the quality control of 1.

  • Paper
  • Guizhou HAO , Xiaojie CHEN , Jianhe SUN , Jipeng HOU , Zhong FENG , Guimin ZHANG
    doi: 10.16522/j.cnki.cjph.2022.07.016

    An ultra-high performance liquid chromatography-mass spectrometry(UPLC-MS) method was established for the determination of migration quantity of hexadecanamide(2), oleamide(3) and stearamide(4) from butyl rubber stopper for injection of epirubicin hydrochloride. The Thermo Hypersil GOLD column(2.1 mm×100 mm,3 μm) was used, and the analysis was carried out in the isocratic elution mode with 0.1% formic acid solution∶methanol(15∶85) as the mobile phase. Electrospray ionization(ESI), positive ion mode acquisition and single ion detection mode (SIM) were used. The results showed that it was linear for 2, 3 and 4 in the ranges of 0.039 2 -0.783 6 μg/ml, 0.040 0 - 0.800 2 μg/ml and 0.037 3 - 0.746 0 μg/ml, respectively. The detection limits of 2, 3 and 4 were 0.011 8, 0.012 0, and 0.011 2 μg/ml, respectively, the mean recoveries(n=12) were 96.28%, 97.21%, and 94.11%, with the RSDs of 3.39%, 4.22%, and 5.63%, respectively. The established method has high sensitivity and good specificity, which provides a reference for the quality control and safety evaluation of epirubicin hydrochloride for injection.

  • Paper
  • Zhifeng CAO , Lipin ZHAO , Ting HE , Baijun MA
    doi: 10.16522/j.cnki.cjph.2022.07.017

    Based on the same formula and process, the three-layer co-extrusion infusion films were prepared with domestic polypropylene(RPB05F middle-layer film material) or imported polypropylene as middle-layer granules, and their properties were compared. The results showed that there was basically no difference between the films prepared from domestic and imported polypropylene granules, and their physical, chemical and biological properties were all met the standards. In addition, the film made by domestic polypropylene granules also had good stability, and the performance did not significantly change during the investigation period. In the extraction test, the contents of antioxidants and metal elements were far less than the limits. The results indicated that domestic polypropylene granules could be applied to the production of three-layer co-extrusion infusion film.

  • Paper
  • Hai WANG , Feng SHEN
    doi: 10.16522/j.cnki.cjph.2022.07.018

    Purified water is very important and widely used in pharmaceutical production as process water, which is crucial for the drug safety. The internationally recognized and generally accepted purified water treatment process,"reverse osmosis" system, was adopted as the model, and the concentrations of several chemical solutions were calculated, such as sodium hypochlorite(NaClO) solution, sodium bisulfite(NaHSO3) solution and sodium hydroxide(NaOH) solution, which must be added in the treatment process to ensure the quality of purified water for pharmaceutical use. From a scientific point of view, the reasons for adding of above chemical solutions were explained, and the concentrations and adding amounts were determined based on the determination results of free chlorine residual and pH values by quantitative analysis method, for guiding the operation procedure of purified water generation.

  • Pharmaceutical Management & Information
  • Ruoxi YAN
    doi: 10.16522/j.cnki.cjph.2022.07.019
  • Pharmaceutical Management & Information
  • Baomei ZHANG , Xiaojun LU
    doi: 10.16522/j.cnki.cjph.2022.07.020
  • Pharmaceutical Management & Information
  • Shuangfeng LOU , Hui CAO , Chuang ZHANG
    doi: 10.16522/j.cnki.cjph.2022.07.021
  • Pharmaceutical Management & Information
  • Minghui SONG , Ning ZHANG , Feng QIN , Yulan JIN , Meicheng YANG
    doi: 10.16522/j.cnki.cjph.2022.07.022
  • Pharmaceutical Management & Information
  • Yang LI , Shaoting CHENG , Ming XU
    doi: 10.16522/j.cnki.cjph.2022.07.023
News